Lilly’s oral rheumatoid arthritis blockbuster contender champions 1-year study

John Carroll

Efficacy results for an experimental drug in development by Eli Lilly and Incyte held up well as patients in a Phase IIb trial were tracked over the course of a full year.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS